Generex Biotechnology Corp (GNBT) Financial Statements (2024 and earlier)

Company Profile

Business Address 10102 USA TODAY WAY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End July 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

4/30/2021
MRQ
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 152981,0462,87917750
Cash and cash equivalents 152981,0462,87917750
Inventory, net of allowances, customer advances and progress billings 7423631210  
Inventory 7423631210  
Intangible current assets      108
Other current assets 3322769622851
Other undisclosed current assets 1653634  (108)
Total current assets: 1,2559741,1882,91125801
Noncurrent Assets
Operating lease, right-of-use asset 38 
Property, plant and equipment 21450032113
Intangible assets, net (including goodwill) 37,55239,3813,1882,911 1,430
Goodwill 34,48938,298    
Intangible assets, net (excluding goodwill) 3,0631,0833,1882,911 1,430
Other undisclosed noncurrent assets 6,3248,7822,1994,272  
Total noncurrent assets: 44,12848,6625,4197,18311,433
TOTAL ASSETS: 45,38349,6366,60710,095262,234
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 23,90819,05611,04510,1738,9518,019
Interest and dividends payable 3,911     
Employee-related liabilities     312357
Accounts payable 1,316   3,7513,157
Accrued liabilities     326326
Other undisclosed accounts payable and accrued liabilities 18,68119,05611,04510,1734,5624,178
Debt 11,166     
Derivative instruments and hedges, liabilities 1,317     
Other undisclosed current liabilities 4,9819,89014,18413,73850 
Total current liabilities: 41,37128,94625,22923,9119,0018,019
Noncurrent Liabilities
Long-term debt and lease obligation 500     
Long-term debt, excluding current maturities 500     
Liabilities, other than long-term debt 1,3177,820  2,0492,363
Derivative instruments and hedges, liabilities 1,3177,820  2,0492,363
Other undisclosed noncurrent liabilities 10,079(7,035)24,96366,060193142
Total noncurrent liabilities: 11,89678524,96366,0602,2422,506
Other undisclosed liabilities  8,158    
Total liabilities: 53,26737,88950,19289,97111,24310,524
Temporary equity, carrying amount 4,0744,074    
Equity
Equity, attributable to parent, including: (11,958)7,673(43,585)(79,876)(11,217)(8,290)
Common stock 826211909825
Additional paid in capital 429,744408,567368,410368,410362,780362,557
Accumulated other comprehensive income 780797798783799809
Accumulated deficit (452,063)(418,728)  (375,704)(372,481)
Warrants and rights outstanding      2,363
Other undisclosed equity, attributable to parent 9,49816,974(412,794)(449,070) (2,363)
Total equity: (11,958)7,673(43,585)(79,876)(11,217)(8,290)
TOTAL LIABILITIES AND EQUITY: 45,38349,6366,60710,095262,234

Income Statement (P&L) ($ in thousands)

4/30/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Revenues  6,204703   
Cost of revenue (580)(4,138)    
Cost of goods and services sold  (645)    
Other undisclosed gross profit 2,661     
Gross profit: 2,0822,065703   
Operating expenses (20,019)(26,411)(3,199)(1,597)(1,903)(3,883)
Operating loss: (17,937)(24,345)(2,496)(1,597)(1,903)(3,883)
Nonoperating income
(Investment Income, Nonoperating)
   700  0
Interest and debt expense (7,104)(7,104)(584)(743)(419)(22)
Loss from continuing operations: (25,041)(31,449)(2,379)(2,340)(2,321)(3,905)
Loss before gain (loss) on sale of properties:(25,041)(31,449)(2,379)(2,340)(2,321)(3,905)
Other undisclosed net income      1,712
Net loss: (25,041)(31,449)(2,379)(2,340)(2,321)(2,193)
Net income attributable to noncontrolling interest 8971,6653856,816  
Other undisclosed net income (loss) attributable to parent (10,088)18,77737,943(81,309)(902) 
Net income (loss) attributable to parent: (34,232)(11,007)35,949(76,833)(3,223)(2,193)
Preferred stock dividends and other adjustments      (340)
Other undisclosed net income available to common stockholders, basic 8971,6653856,816  
Net income (loss) available to common stockholders, diluted: (33,335)(9,341)36,334(70,016)(3,223)(2,533)

Comprehensive Income ($ in thousands)

4/30/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Net loss: (25,041)(31,449)(2,379)(2,340)(2,321)(2,193)
Comprehensive loss: (25,041)(31,449)(2,379)(2,340)(2,321)(2,193)
Comprehensive income, net of tax, attributable to noncontrolling interest 8971,6653856,816  
Other undisclosed comprehensive income, net of tax, attributable to parent      37
Comprehensive income (loss), net of tax, attributable to parent: (24,144)(29,784)(1,994)4,476(2,321)(2,157)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: